Genmab A/S Sponsored ADR GMAB 深 沪
已收盘 02-06 16:00:00 美东时间
30.93
-0.040
-0.13%
华盛通- 最 高35.43
- 今 开30.94
- 成交量 158.03万股
- 最 低 30.35
- 昨 收 30.97
- 总市值 2025.92万
- 52周最高 35.43
- 市盈率 静 42.73
- 换手率 241.26%
- 52周最低 0.00
- 委 比 -9.15%
- 总股本 0.01亿
- 历史最高 35.43
- 量 比 1.24
- 振 幅 16.40%
- 历史最低 0.00
- 每 手 1
- 风险率 5.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Genmab Cancer Drug DARZALEX Posts $14.4B in Global Sales in 2025
Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename
01-21 19:27
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer
Incyte reported positive results from a trial of tafasitamab as a first-line treatment for adults with DLBCL. No new safety issues were seen.
01-06 00:59
Genmab Prunes Pipeline, Sharpens Focus On Late-Stage Cancer Assets
Genmab will discontinue clinical development of acasunlimab to focus on more promising late-stage programs in its portfolio.
2025-12-30 01:32
Genmab A/S Plans To Discontinue Further Clinical Development Of Acasunlimab
Genmab A/S (NASDAQ:GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab's strategic focus on the most value‑creating opportunities in its
2025-12-29 21:17
Bristol Myers' Cancer Breakthrough Breyanzi Just Won Its Fifth FDA Approval
FDA approves Breyanzi, a CAR T cell therapy for relapsed or refractory marginal zone lymphoma. It has a high response rate.
2025-12-05 21:36
MHRA Approves Tisotumab Vedotin For The Treatment Of Cervical Cancer
https://www.gov.uk/government/news/mhra-approves-tisotumab-vedotin-for-the-treatment-of-cervical-cancer
2025-12-02 23:29
FDA Approves Epcoritamab-bysp For Follicular Lymphoma Indications
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-epcoritamab-bysp-follicular-lymphoma-indications
2025-11-18 23:24
Genmab进入收购药物开发商Merus的深入谈判阶段
生物制药公司Genmab （GMAB） 据悉已进入收购荷兰癌症药物开发商Merus （NASDAQ：MRUS） 的深入谈判阶段。今年市值增长60%的Merus预计很快将宣布并购协议。此次收购将增强Genmab的肿瘤产品组合，尽管仍可能出现其他竞标者。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-09-29 23:03
Breaking Down Genmab: 4 Analysts Share Their Views
In the preceding three months, 4 analysts have released ratings for Genmab (NAS...
2025-03-12 02:01
William Blair Upgrades Genmab to Outperform
William Blair analyst Matt Phipps upgrades Genmab (NASDAQ:GMAB) from Market Perform to Outperform.
2025-03-11 23:23
